microRNA-19b-3p (miR-19b-3p)

microRNA-19b-3p is a small, single-stranded, non-coding RNA molecule (approximately 21–23 nucleotides in length), and a member of the miR-17-92 cluster[3][7]. It regulates gene expression at the post-transcriptional level by binding to complementary sequences in target mRNAs, promoting mRNA degradation or inhibiting translation[7]. miR-19b-3p is widely expressed in mammalian tissues and modulates key biological processes such as cell proliferation, apoptosis, differentiation, immune signaling, and inflammation[3][5][6]. It has oncogenic properties via suppression of tumor suppressors (e.g., PTEN)[3][6], contributes to cardiovascular remodeling (e.g., in heart failure, hypertrophy) by targeting genes involved in fibrosis, hypertrophy, and cell survival[1][4][6], and is implicated in psychiatric and neuroinflammatory pathways[5]. It has strong potential as a biomarker for the diagnosis and prognosis of diseases such as breast and prostate cancer, heart failure, and psychiatric disorders due to its detectable and disease-associated alterations in blood/plasma[2][3][4][5]. Therapeutic targeting is under investigation, primarily through RNA-based technology (e.g., miRNA mimics, antagomirs), but no approved drugs exist that specifically target miR-19b-3p at present. Safety concerns include its broad regulatory network and challenges in delivery and tissue specificity of RNA therapeutics[6].

Other names

hsa-miR-19b-3pmiR-19b

Antisense oligonucleotides or miRNA mimics to modulate its activity (primarily experimental)